{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT03612154","nct_id":"NCT03612154","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct03612154. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Subjects will be treated with lorlatinib 100mg PO daily. A cycle will be defined as 28-days for the convenience of analysis.","label":"Lorlatinib","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2023-12-31","type":"ESTIMATED"},"conditions":["Nonsmall Cell Lung Cancer"],"enrollment":{"count":35,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Lorlatinib","otherNames":[],"type":"DRUG"}],"last_update":"2022-04-06","lead_sponsor":"National Cancer Center, Korea","official_title":"A Phase II Study of Lorlatnib in ROS1 Rearranged Advanced NSCLC","overall_status":"UNKNOWN","phases":["PHASE2"],"primary_completion_date":{"date":"2022-12-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"ORR","timeFrame":"from Cycle1 Day 1 until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months\")."}],"references":[{"citation":"Ahn BC, Kim YJ, Lee Y, Suh KJ, Kim SH, Kim DW, Kim TM, Lee KH, Han JY. Lorlatinib in Tyrosine Kinase Inhibitor-Naive Advanced ROS1-Positive Non-Small Cell Lung Cancer: A Phase 2 Nonrandomized Clinical Trial. JAMA Oncol. 2026 Jan 1;12(1):84-89. doi: 10.1001/jamaoncol.2025.5097.","pmid":"41296331","type":"DERIVED"}],"start_date":{"date":"2019-05-02","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Lorlatinib in ROS1 Rearranged NSCLC","url":"https://clinicaltrials.gov/study/NCT03612154"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct03612154"}